Experimental and Molecular Medicine (Feb 2019)

Inhibition of β-site amyloid precursor protein cleaving enzyme 1 and cholinesterases by pterosins via a specific structure−activity relationship with a strong BBB permeability

  • Susoma Jannat,
  • Anand Balupuri,
  • Md Yousof Ali,
  • Seong Su Hong,
  • Chun Whan Choi,
  • Yun-Hyeok Choi,
  • Jin-Mo Ku,
  • Woo Jung Kim,
  • Jae Yoon Leem,
  • Ju Eun Kim,
  • Abinash Chandra Shrestha,
  • Ha Neul Ham,
  • Kee-Ho Lee,
  • Dong Min Kim,
  • Nam Sook Kang,
  • Gil Hong Park

DOI
https://doi.org/10.1038/s12276-019-0205-7
Journal volume & issue
Vol. 51, no. 2
pp. 1 – 18

Abstract

Read online

Alzheimer’s disease: Promising therapeutic compounds found in plants Compounds extracted from bracken fern block the activity of three enzymes associated with Alzheimer’s disease (AD). Because AD is a complex and multifactorial disease, a multitarget-directed approach is an attractive strategy for the development of disease-modifying therapeutics. A study led by Gil Hong Park, Korea University, Seoul, and Nam Sook Kang, Chungnam National University, Daejon, revealed that pterosin derivatives could reduce the activity of β-site amyloid precursor protein cleaving enzyme 1, acetylcholinesterase and butyrylcholinesterase in a concentration-dependent manner. Furthermore, the fern-extracted compounds did not cause cellular toxicity and were able to cross the blood–brain barrier, which is impermeable to most drugs, to reach the brain. Future studies will determine whether they can be developed into drugs to simultaneously engage various AD targets in animal models of the disease.